

**Professor Graham R Foster
BA, FRCP, PhD**

Curriculum Vitae

August 2006

Name: Professor Graham Russell Foster

Date of Birth: 15 September 1959

Current Position: Professor of Hepatology, Queen Marys School of Medicine and Dentistry and Honorary Consultant Physician, Barts and The London NHS Trust

Qualifications: BA (Oxon) 1980
MB BS 1983
MRCP 1986
PhD 1992
FRCP 1999

Overview

Experienced clinical scientist with over £500,000 peer reviewed grants over the last 3 years

Clinician with expertise in the management of patients with general medical and hepatological disorders. I provide a specialised referral service for patients with liver disease and I manage both local patients as well as tertiary referrals from around the UK.

Expertise in clinical research – I have initiated and managed a number of multi-centre clinical trials including the UK Amantadine Study, which was the first multi-centre trial for patients with chronic hepatitis C to be completed in the UK.

Established international reputation in the field of viral hepatitis – I am sub-editor of The Journal of Viral Hepatitis, I consult for a number of international pharmaceutical companies and I have served on four data safety review monitoring boards for international clinical trials

Committed teacher with experience in bedside, small group and lecture teaching.

Education

Preclinical – Exhibitioner at Wadham College, Oxford, 1977-1980

Clinical – The London Hospital Medical School, London, 1980 – 1983

Science (PhD) – The Imperial Cancer Research Fund, London, 1988-1992

Previous Appointments

Jan 1995 – December 2002

Senior Lecturer (latterly Reader) in Hepatology at Imperial College of Science, Technology and Medicine, St Mary's Hospital, London

Jul 1992 - Dec 1994

Lecturer and honorary senior registrar, The Liver Unit, Imperial College of Science, Technology and Medicine, St Mary's Hospital, London
Consultant – Prof HC Thomas

Aug 1988- Jul 1992

Clinical Research Fellow at The Imperial Cancer Research Fund, London.
Supervisors - Dr GR Stark, Prof HC Thomas

Aug 1987 – Jul 1988

Registrar in Nephrology at St Mary's Hospital, London
Consultant – Dr R. Gabriel, Dr B. Hulme

Aug 1986 – Jul 1987

Registrar in gastroenterology and general medicine at St Charles Hospital, London
Consultant – Dr JH Baron

Feb 1986 – Jul 1986

SHO in Nephrology at The Hammersmith Hospital, London
Consultants – Prof K. Peters, Dr A. Rees, Dr M. Lockwood.

Feb 1985 – Jan 1986

SHO in general medicine at Edgware General Hospital, London
Consultant – Dr J. Lewis

August 1984 – Jan 1985

SHO in A/E at Kings College Hospital, London
Consultant – Dr E. Glucksman

Feb 1984 – Jul 1984

HO in surgery at King Georges Hospital, Ilford
Consultant – Mr E Slater

Aug 1983 – Jan 1984

HO in medicine at The London Hospital
Consultant – Prof R. Cohen

Membership of Professional Bodies and other appointments

Fellow of the Royal College of Physicians
Member of the European Association for the Study of the Liver
Member of the American Association for the Study of the Liver

Honorary consultant at The Royal Free Hospital, London

Sub editor, The Journal of Viral Hepatitis
Editorial board member, The Journal of Interferon and Cytokine Research
Editorial board member, Viral Hepatitis Update

Member of the UK Department of Health Hepatitis Advisory Panel.
Chairman North East London Hepatology Committee
Member of the London 'Best Practice Guide for Hepatitis C' Committee
Member of The Children's Liver Disease Foundation Advisory Board
Member of The Haemophilia Society Medical Advisory Panel
Member of the medical advisory board to The National Hepatitis C Centre

Member of The British Association for the Study of the Liver committee (1999 – 2002)

Teaching

I enjoy teaching and am involved in undergraduate and post graduate teaching. I am an active member of the QMUL Teaching Committee and I am responsible for organising clinical teaching for students attached to our medical firm. I am responsible for the hepatology module of the QMUL MSc in Gastroenterology course. I regularly run informal 'pre finals' revision tutorials that are popular with students.

I have supervised several post graduate students including:-

Morris Paterson – 1997-2000 (PhD awarded)
Dimitris Platis – 1998 – 2001 (PhD awarded)
Conrad Germain 2000 – 2003 – PhD student. Joint supervision with Dr G. Lombardi, The Hammersmith Hospital.
Meleri Jones 2002-2005 PhD student
Peter Smith 2002-2005 PhD student

I have acted as external and internal examiner for a number of PhD and MD students and I have been invited to lecture widely throughout the world on various aspects of viral liver disease.

Research

Basic scientific research

a) Immunomodulatory properties of the different interferon alpha subtypes.

My research group is currently investigating the immunomodulatory effects of the different Type I interferons. We hypothesise that the Type I interferons are involved in the initiation and maintenance of immune responses and that the different subtypes have different effects. Work completed to-date has shown that:

- IFN α 8 and IFN β induce proliferation in primary B cells
- The interaction between dendritic cells and CD4+ T cells leads to the production of interferon α and different interferon subtypes may have different effects on T cell development. We have recently developed PCR based assays that allow us to examine the production of different type I interferons and work is under way to examine factors that modify the interferon that is produced (work performed in collaboration with Prof R. Lechler/Dr G. Lombardi, The Hammersmith Hospital)

b) Effects of the hepatitis C virus on the cellular response to interferon

We have analysed the effects of different patient derived HCV sequences on the cellular response to interferon and work is under way to characterise these effects in more detail. We are currently expanding our studies on viral inhibitors of the interferon response to include other flaviviridae, particularly Dengue virus.

2 – Clinical research

My clinical research is focussed on the management of chronic hepatitis C infection. I have developed, implemented and audited clinical guidelines for the treatment of chronic hepatitis C which have been widely adopted nationally and internationally. My current research is aimed at refining and improving current therapeutic strategies. On going research includes:

- Multi-centre, randomised, controlled clinical trials of novel adjuncts to pegylated interferon therapy.
- Factors responsible for quality of life changes in hepatitis C. My group published the first clinical proof that chronic HCV is associated with impairments in quality of life and work is now under way to identify the mechanisms underlying these changes.

Grants

1 - Principal Investigator/supervisor

Wellcome Trust (with Prof. R.Lechler and Dr G. Lombardi) – ‘Type I Interferons and helper T cell polarisation: a potential target for immune manipulation’

Oct 2000 – Oct 2003 - £153,000

Wellcome Trust – Research Fellowship for Dr Mike Jacobs – ‘The Molecular Basis of Dengue haemorrhagic fever/Dengue shock syndrome: viral replication and innate antiviral defences’ -£400,000 2001 –2004

European Commission (HEPATC-RESIST) – ‘Studies into the mechanisms underlying interferon resistance in patients with chronic hepatitis C’ – Euro 225,000 2002 –2005

Roche Pharmaceuticals – ‘Clinical trials of pegylated interferon’ April 2002 – March 2005 £160,000

Maxygen – ‘Differential effects of different type I interferons in human tissue’ August 2004 – August 2005 £150,000

Phynova Group PLC – ‘Evaluation of the clinical efficacy of a herbal preparation in patients with chronic HCV infection’ April 2002 – April 2005 £150,000

Roche Pharmaceuticals – ‘Clinical trial of interferon plus ribavirin and amantadine in the treatment of patients with chronic hepatitis C’ Jan 2001 – Jan 2004. £30,000

Sumitomo Pharmaceuticals – ‘ Immunological studies of interferon alpha subtypes in healthy subjects’ January 2001 – December 2003. £54,000

Roche Pharmaceuticals – ‘Mechanisms of Action of Type I Interferons in chronic HCV infection’ October 2006 - October 2008. £200,000

Department of Health – ‘Case finding and prevalence of chronic viral hepatitis in South Asians living in the UK’ – October 2006 – April 2008 £140,000

The National Lottery – ‘Improving knowledge and understanding of chronic hepatitis C in ethnic minority groups from Pakistan and Bangladesh in London’ (Collaborative grant with The Hepatitis C Trust’ October 2006 – October 2009 £350,000

2 - Collaborative Grants

NHS R and D (with Prof Thomas and Dr J. Main) – ‘Health benefits from antiviral therapy for mild chronic hepatitis C’ May 1998 – June 2003 - £1,000,000

NHS R and D (with Dr M. Blomley et al) – ‘Non-invasive assessment of hepatitis C liver disease’ Oct 2001 – Oct 2004 - £75,000

The National Lottery (in association with The Hepatitis C Trust). Improving knowledge and understanding of chronic hepatitis C in ethnic minority groups from Pakistan and Bangladesh in London August 2006 – August 2009 £343,000

Publications

Books

R English, **GR Foster**. Living with hepatitis C. Robinson Publishers, London. 1997

GR Foster (editor) Bailliere's Clinical Gastroenterology: Hepatitis C. 2000

GR Foster, RD Goldin Management of Viral Hepatitis Martin Dunitz Publishers, London 2002

M Bassendine, **GR Foster**, A Miles. The Effective Management of Hepatitis C Infection. 2003.

Chapters in books

GR Foster, HC Thomas. The role of interferon alpha - in virus elimination: viral inhibitors resulting in persistent infection." In Immunology and Liver, Falk Symposium 70 (Kluwer Academic Publishers, London.) 1992,131-136

GR Foster, HC Thomas. Treatment of hepatitis C with interferon: mechanism of action of interferon. In Proceedings of the 1993 International Symposium on Viral Hepatitis and Liver disease. (Springer-Verlag, Tokyo)

GR Foster, MR Jacyna, HC Thomas. Interferon treatment of hepatitis. Baillieres Clinical Infectious Diseases (Baillieres, London)

GR Foster. Inhibition of the cellular response to interferon by hepatitis B polymerase. Modulation of MHC Antigen Expression and Disease Edited by GE Blair and DJ Maudsley. (Cambridge University Press)

JA Waters, **GR Foster**, MR Thursz, HC Thomas. Hepatitis B virus infection and immunity. In Human Tumour Viruses Ed DJ McCance ASM Press, Washington

GR Foster, HC Thomas. Chronic hepatitis B viral infection: cytokines and therapy. In Hepatitis B Virus Ed R Koshy and WH Caselmann. Imperial College Press, London

GR Foster, J Main, HC Thomas. The management of chronic hepatitis C. National Association of Fundholding Practices Yearbook 1998. Scorpio Publishers, Thornton Heath, Surrey.

GR Foster, RD Goldin, HC Thomas. The hepatotropic viruses: epidemiology, natural history and virology. In Pathology of Viral Hepatitis Ed RD Goldin, HC Thomas, MA Gerber. Arnold Publishers, London.

Substantial Journal Papers

Oliveira DBG, **Foster G**, Savill J, Syme PD, Taylor A. Membranous nephropathy caused by mercury containing skin lightening cream. Postgraduate Medical Journal 1987;63: 303-304.

Foster GR. Behcets colitis with oesophageal ulceration treated with sulphasalazine and cyclosporin. *J Roy Soc Med* 1988;81:545-546

Foster GR, Goldin RD, Oliveira DBG. Serum F protein: a new sensitive and specific test of hepatocellular damage. *Clin Chim Acta* 1989;184: 85-92.

Beckett GJ, **Foster GR,** Hussey AJ, Oliveira DBG, Donovan JW, Prescott LF, Proudfoot AT. Plasma glutathione S-transferase and F protein are more sensitive than aminotransferases as markers of paracetamol (acetaminophen)-induced liver damage. *Clin Chemistry*, 1989; 35: 2186-2189.

Foster GR, Carmichael DJS, Kermode A, Hulme B, Gabriel JRT, Cattell V. Extensive crescent formation with antifibrinolytic therapy in a case of diffuse endocapillary glomerulonephritis. *Nephrology, Dialysis and Transplantation*, 1990;5:152-154.

Foster GR, Goldin RD, Freeth CJ, Nieman EA, Oliveira DBG. Liver damage in long-term anticonvulsant therapy: a serological and histological study. *Q J Med*, 1991;288: 315-322

Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR. Expression of the terminal protein of hepatitis B inhibits the cellular response to interferons and double stranded RNA *Proc Nat Acad Sci, USA*, 1991;88: 2888-2892

Ackrill AM, **Foster GR,** Stark GR, Kerr IM. The 12S product of the adenovirus E1A gene inhibits the cellular response to interferon. *Nucleic Acid Research* 1991;19:4387-4393

Cooper CM, **Foster GR,** Riddington AE, Kenny M, Oliveira DBG. Serum F protein concentration following halothane or isoflurane anaesthesia. *Clin Chim Acta*, 1991;202:73-82

Foster GR, Goldin RD, Hay A, McGarvey M, Stark GR, Thomas HC. Expression of the terminal protein of hepatitis B virus is associated with a failure to respond to interferon therapy. *Hepatology*, 1991;17: 757-762

Block TM, Platt FM, Xuanyong L, Gerlich WH, **Foster GR,** Blumberg B, Dwek RA. The secretion of human hepatitis B virus is inhibited by the imino sugar, N-butyldeoxynojirimycin. *Proc Nat Acad Sci, USA*, 1994;91: 2235-2239

Cook HT, Ebrahim H, Jansen AS, **Foster GR,** Largen P, Cattell V. Expression of the gene for inducible nitric oxide synthase in experimental glomerulonephritis. *Clin Exp Immunol*, 1994; 97: 315-320

Foster GR, Thomas HC. Hepatitis C virus infection. Treatment with interferon reduces viraemia (letter) *BMJ*. 1994; 308: 1710

Teare JP, Price DA, **Foster GR,** McBride M, Goldin RD, Main J. Reversible

AIDS-related sclerosing cholangitis. *J-Hepatol.* 1995; 23: 209-11

Booth JL, **Foster GR**, Brown J, Kumar U, Galassini R, Thomas HC. Effect of hepatitis C virus genotype and viraemia on disease severity and response to interferon therapy *Gut.* 1995;36: 427-32

Rani MRS, **Foster GR**, Leung S, Leaman D, Stark GR, Ransohoff RM. Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha *J-Biol-Chem.* 1996; 271: 22878-84

Thomas HC, **Foster GR**, Sumiya M, McIntosh D, Jack DL, Turner MW, Summerfield JAS. Mutation of gene for mannose binding protein associated with chronic hepatitis B viral infections. *Lancet* 1996;348:1417-1419

Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa D, Liao MJ, Stark GR, Leadbeater L, Thomas HC. Different relative activities of human cell derived interferon-alpha subtypes: interferon alpha 8 has very high antiviral potency. *J Interferon and Cytokine Res.* 1996;16: 1027-1033

Goldin RD, Levine TS, **Foster GR**, Thomas HC. Granulomas and hepatitis C. *Histopathology* 1996;28:265-267

Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. The management of chronic hepatitis C: clinical audit of a biopsy based management algorithm. *BMJ* 1997;315: 453-458

Booth JCL, **Foster GR**, Levine T, Thomas HC, Goldin RD. The relationship of histology to genotype in chronic HCV infection. *Liver* 1997;17:44-151

Schulte-Frohlinde E, **Foster GR**. Spontaneous seroconversion in chronic hepatitis B: role of mutations in precore/core. *Dig Dis Sci* 1998;29:495-500

Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life. *Hepatology* 1998;27:209-212

Hibbert L, **Foster GR**. Human Type I interferons differ greatly in their effects on the proliferation of primary B cells. Type I interferons. *J Interferon and Cytokine Research* 1999;19:309-319

Paterson, M., Laxton, CD, Thomas HC, Ackrill AM, **Foster GR**. Hepatitis C virus NS5A protein inhibits interferon antiviral activity but the effects do not correlate with clinical response. *Gastroenterology* 1999;117:1-13

Ward C, Cotzias T, Regan L, Tudor-Williams G, Hargreaves S, **Foster GR**. Prevalence of hepatitis C amongst pregnant women attending an inner London Obstetric Department: Uptake and Acceptability of named antenatal testing. *Gut* 2000 47:277-280

Foster GR, Germain C, Jones M, Lechler RI, Lombardi GL. Human T cells elicit interferon alpha secretion from human dendritic cells following cell to cell interactions. *Eur J Immunol* 2000. 30;3228-3235

Forton D, Allsop J, Main J, **Foster GR**, Thomas H, Taylor-Robinson S. Evidence

for a cerebral effect of the hepatitis C virus. *Lancet* 2001;358:38-39.

Leyland M, Török E, J JA, **Foster GR**. Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity. *Eye* 2001;15:202-205.

Paterson M, Laxton C, Goldin RD, Ackrill AM, **Foster GR**. Selection of HCV NS5A quasispecies during IFN therapy in patients with chronic HCV. *Dig Dis Sci* 2001;46(7):1399-408.

Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon I, Irving WL, Goldin RD, **Foster GR**. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. *J Hepatol* 2001;35(4):512-6.

Schulte-Frohlinde E, Seidler B, Burkard I, Freilinger T, Lersch C, Erfle V, **Foster GR**, Classen M Different activities of type I interferons on hepatitis B virus core promoter regulated transcription Cytokine. 2002 Feb 21;17(4):214-20.

Dick EA, Joarder R, De Jode M, Taylor-Robinson SD, Thomas HC, **Foster GR**, Gedroyc WMW. MR-guided laser Thermal Ablation of primary and secondary liver tumours. *Clinical Radiology* 2003; (58): 112-120

Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, Contreras M, Dusheiko G, **Foster GR**, Gill N, Kemp K, Main J, Murray-Lyon I, Nelson M. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. *J Medical Virology* 71:49-55 2003.

Platis D, **Foster GR**. High Yield Expression, Refolding and Characterization of Recombinant Interferon $\alpha 2/\alpha 8$ hybrids in *Escherichia coli*. *Protein Expression and Purification* 31 (2003) 222-230.

Platis D, **Foster GR**. Activity of Hybrid Type 1 Interferons in Cells Lacking Tyk2: A Common Region of IFN- $\alpha 2/8$ Hybrids Can Behave Like IFN- β . *Journal of Interferon and Cytokine Research* 23 (655-666) 2003.

Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, **Foster GR**, Zeuzem S, Berg T, Di Marco V, Cino N, Andriulli A. Combination therapy with Amantadine and Interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from 6 clinical trials. *J Hepatol* 2004; 40:478-483

D'Souza RF, Glynn MJ, Alstead E, Osonayo C, **Foster GR**. Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. *QJM*. 2004 Jun;97(6):331-6.

Reed JR, Vukmanovic-Stejic M, Soares MV, Cook JE, Fletcher JM, Orteu CH, Jackson S, Birch K, **Foster GR**, Salmon M, Beverley PCL, Rustin MHA, Akbar AN. Accelerated Telomere Erosion Drug Extra-Lymphoid T Cell Turnover in Humans. *J Exp Med* 2004;199:1433-43

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, **Foster GR**, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J. Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C. *Am J Gastroenterology* 2004;99:1490-1496

Foster GR, Masri S, David R, James M, Datta A, Runkell L, deDios C, Sizing I, Jones M, Lombardi G, Marelli-Berg FM, IFN-alpha subtypes differentially affect human T cell motility. *J Immunol* 2004 173:1663-1670

Caronia S, McGarvey MJ, Goldin RD, **Foster GR** Intrahepatic expression of hepatitis C antigens is associated with suppression of apoptosis despite expression of Fas and HLA antigens. *Journal of Viral Hepatitis* 2004 11:511-518

Pollara G, Jones M, Kwan A, Minson T, Coffin RS, **Foster G**, Chain B, Katz DR. Type I IFN from HSV-1 infected myeloid dendritic cells initiates paracrine activation. *J Immunol* 2004;173;4108-19

Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, **Foster GR**, Thomas HC, Cosgrove DO, Blomley MJ Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. *Gut* 2005;54:128-133

Foster GR, Pegylated interferons: Chemical and Clinical Differences. *Aliment Pharmacol Ther* 2004;20:825-30

D'Souza RF, Feakins R, Mears L, Sabin CA, **Foster GR**. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. *Aliment Pharmacol Ther*. 2005;21:519-24.

D'Souza R, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C, **Foster GR**. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy. *Aliment Pharmacol Ther*. 2005;21:43-7.

Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, **Foster GR**, Jacobs M. Dengue virus inhibits interferon alpha signalling by reducing STAT2 expression. *J Virol* 2005;79:5414-20

Scott K, Manunta M, Germain C, Smith P, Jones M, Mitchell P, Dessi D, Branigan Bamford K, Lechler RI, Fiori PL, **Foster GR**, Lombardi G. Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. *Immunology*. 2005 Oct;116(2):245-54.

D'Souza R, Sabin CA, **Foster GR**. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. *Am J Gastroenterol*. 2005 Jul;100(7):1509-15.

D'Souza R, Sinnott P, Glynn MJ, Sabin CA, **Foster GR**. An unusual form of autoimmune hepatitis in young Somalian men. *Liver Int*. 2005 Apr;25(2):325-30.

D'Souza R, Glynn MJ, Alstead E, Kumar P, Sabin CA, Ushiro-Lumb I, Mears L, Feakins R, **Foster GR**. Natural History of Chronic Hepatitis C Infection: Long Term Follow-up of Asian Patients Infected in Childhood. *Clin Gastroenterol Hepatol* 2005;3:910-7

Tamir A, Jordan WJ, Ritter M, Habib N, Lechler RI, **Foster GR**, Lombardi G. Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity. *Clin Exp Immunol*. 2005 Dec;142(3):471-80.

Szmaragd C, **Foster GR**, Manica A, Bartholomeusz A, Nichols RA, Balloux Genome-wide characterisation of Hepatitis B mutations involved in clinical outcome. *Heredity*. 2006 Aug 9; [Epub ahead of print]

Hollander A, **Foster GR**, Weiland O Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. *Scand J Gastroenterol*. 2006 May;41(5):577-85.

Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a(40KD) and ribavirin. *Scandinavian Journal of Gastroenterology* 2006 In press

Review articles

GR Foster, WF Carman, HC Thomas. Replication of hepatitis B and delta viruses: appearance of viral mutants. *Seminars in Liver Disease*,1991; 11: 121-127

GR Foster. Resistance of hepatitis B virus infection to treatment with interferon alpha. *Interferons and Cytokines* 1992; 22: 25-28

GR Foster, HC Thomas. Recent advances in the molecular biology of hepatitis B virus: mutant viruses and the host response. *Gut*.1993;34:1-3

GR Foster, HC Thomas. Effects of hepatitis B and hepatitis C virus replication on the actions of interferon. *Antiviral Research* 1994;24:131-136

GR Foster, NB Finter. Are all Type I human interferons equivalent ? *J Viral Hepatitis* 1998; 5;143-152

GR Foster. Interferons in host defence. *Seminars in Liver Disease* 1998;17:287-295

GR Foster. Amantadine in the treatment of patients with chronic hepatitis C. *Italian Journal of Gastroenterology and Hepatology* 1998;30:614-615

GR Foster, HC Thomas, ME Toruk, Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alpha therapy *Comments. Hepatology* 1999;29;1333-1334

GR Foster. Hepatitis C infection: side effects and quality of life. *J. Hepatol.* 1999 S1

GR Foster, RPM Negus. Hepatitis C: The real millennium bug. *Health Service Journal* 2000.*

GR Foster The Clinical Effectiveness of Pegylated Interferons in the Management of Chronic Hepatitis C. *Aids and Hepatitis Digest* 2002 *

GR Foster Management of chronic hepatitis C – time for a change ? *J Viral Hep* 2002;9:82-83

GR Foster Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. *Expert Opinion on Pharmacotherapy* May 2003 Vol. 4 No 5.

GR Foster Past, present and future hepatitis C treatments *Seminars in Liver Disease Supplement* 2002 (In press) *

GR Foster The clinical effectiveness of pegylated interferons in the management of chronic hepatitis C. *Aids and Hepatitis Digest* 2002;89;3-5 *

GR Foster Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. *Expert Opinion on Pharmacotherapy* 2003;4:685-691

GR Foster, Thomas H, Platis D. Mechanisms of action of interferon and nucleoside analogues. *J Hepatol* 2003;

R D'Souza R, **GR Foster** Diagnosis and treatment of hepatitis C. *J R Soc Med.* 2004 Jul;97(7):223-5

R D'Souza R, **GR Foster** Diagnosis and treatment of chronic hepatitis B. *J R Soc Med.* 2004 Jul;97(7):318-21

Foster GR Past, present, and future hepatitis C treatments. *Semin Liver Dis.* 2004;24 Suppl 2:97-104. .

Smith PL, Lombardi G, **Foster GR.**
Type I interferons and the innate immune response--more than just antiviral cytokines. *Mol Immunol.* 2005 May;42(8):869-77. Epub 2005 Jan 13. Review.

Foster GR.
Apoptotic cell death: the caspase-cleavage "gold rush". *Lancet.* 2005 Apr 9-15;365(9467):1293-4.

Peer reviewed letters

D'Souza RF, Glynn MJ, Alstead E, Foster GR, Ushiro-Lumb I. Improving hepatitis C services across the UK: response to a walk-in HCV testing service. *Gut.* 2004 Sep;53(9):1388.

D'Souza RF, Glynn MJ, Alstead E, Foster GR, Osonayo C. Improving general practitioners' knowledge of chronic hepatitis C infection. *QJM.* 2004 Aug;97(8):549-50.

TaylorRobinson SD, **Foster GR**, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. (letter) *Lancet* 1997;350:1142-1143

Gorchein A, **Foster GR.** Liver failure in protoporphyria treatment with oral charcoal. *Hepatology* 1999; 29: 995-996.

Foster GR, Tudor-Williams G, White J, Regan L. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus *BJOG* 2003;110:91

Foster GR, Chapman R. Combination treatment for hepatitis C is not being given. *BMJ* 2000 Oct 7;321 (7265):899.